Amy Sobota
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Amy Sobota has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Ellis J. Neufeld
Department of Hematology St. Jude Children's Research Hospital Memphis Tennessee USA
7 shared publications - Charles T. Quinn
Division of Hematology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
4 shared publications - Matthew M. Heeney
Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA
4 shared publications Alyssa Patterson
Boston University School of Public Health Boston Massachusetts
3 shared publicationsDionne A. Graham
Department of Pediatrics, Harvard Medical School, Boston, Massachusetts
3 shared publications- Aimee K. Hildenbrand
Center for Healthcare Delivery Science, Nemours Children’s Health, Delaware, DE 19803, USA
2 shared publications
Latest Publications
- Open Access
- 6 March 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (5) , e31639
Engaging Parents of Children With Sickle Cell Disease in Shared Decision‐Making for Hydroxyurea: The ENGAGE‐HU Study
Background: Guidelines recommend that hydroxyurea be offered to children with sickle cell disease (SCD) as early as 9 months of age using shared decision‐making. To help clinicians implement shared decision‐making with parents, we developed the Hydroxyurea Shared Decision‐Making (H‐SDM) toolkit. We evaluated its effectiveness on parent decisional uncertainty, perceptions of shared decision‐making, hydroxyurea knowledge, and the likelihood of being offered and prescribed hydroxyurea. Procedure: Sites began in the usual care condition (clinician pocket guide) before crossing over to the H‐SDM toolkit condition between 2018 and 2022. Caregivers of children with SCD (birth to 5 years) eligible for hydroxyurea completed assessments at baseline, immediately after discussing hydroxyurea with their clinician, and 3–7 months later. Results: Participants included 176 caregivers (93.2% female, 89% Black); most toolkit participants were enrolled during the pandemic ( n = 81). There were no statistically significant differences between conditions on parent decisional uncertainty, perceptions of shared decision‐making, or hydroxyurea knowledge ( p ‐values >0.05). However, there was a clinically important difference in certainty, with higher decisional uncertainty in the usual care group. A greater proportion of participants enrolled during usual care were offered (80.7%) and prescribed hydroxyurea (48.2%), compared to 58.7% offered and 39.7% prescribed during the toolkit condition ( p ‐values ≤0.01). Conclusions: Findings suggest the toolkit may help parents feel more confident in deciding about hydroxyurea. Given the significant impacts of the COVID‐19 pandemic on study implementation, the impact on hydroxyurea uptake requires additional exploration. Ultimately, the H‐SDM toolkit may be most beneficial for clinics that do not routinely use a shared decision‐making process for those considering hydroxyurea.
- 6 March 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (5) , e31639
Open AccessEngaging Parents of Children With Sickle Cell Disease in Shared Decision‐Making for Hydroxyurea: The ENGAGE‐HU Study
Background: Guidelines recommend that hydroxyurea be offered to children with sickle cell disease (SCD) as early as 9 months of age using shared decision‐making. To help clinicians implement shared decision‐making with parents, we developed the Hydroxyurea Shared Decision‐Making (H‐SDM) toolkit. We evaluated its effectiveness on parent decisional uncertainty, perceptions of shared decision‐making, hydroxyurea knowledge, and the likelihood of being offered and prescribed hydroxyurea. Procedure: Sites began in the usual care condition (clinician pocket guide) before crossing over to the H‐SDM toolkit condition between 2018 and 2022. Caregivers of children with SCD (birth to 5 years) eligible for hydroxyurea completed assessments at baseline, immediately after discussing hydroxyurea with their clinician, and 3–7 months later. Results: Participants included 176 caregivers (93.2% female, 89% Black); most toolkit participants were enrolled during the pandemic ( n = 81). There were no statistically significant differences between conditions on parent decisional uncertainty, perceptions of shared decision‐making, or hydroxyurea knowledge ( p ‐values >0.05). However, there was a clinically important difference in certainty, with higher decisional uncertainty in the usual care group. A greater proportion of participants enrolled during usual care were offered (80.7%) and prescribed hydroxyurea (48.2%), compared to 58.7% offered and 39.7% prescribed during the toolkit condition ( p ‐values ≤0.01). Conclusions: Findings suggest the toolkit may help parents feel more confident in deciding about hydroxyurea. Given the significant impacts of the COVID‐19 pandemic on study implementation, the impact on hydroxyurea uptake requires additional exploration. Ultimately, the H‐SDM toolkit may be most beneficial for clinics that do not routinely use a shared decision‐making process for those considering hydroxyurea.
- 25 September 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (12) , e31348
Adherence outcomes of a liquid hydroxyurea delivery program in a pediatric population
Background: Hydroxyurea remains underutilized in the pediatric sickle cell population despite its well‐known efficacy in decreasing sickle cell complications and hospitalizations. Access to refills and liquid formulation remains a critical barrier to adherence to hydroxyurea regimens. This study was undertaken to determine the clinical impact of home‐delivering compounded liquid hydroxyurea (LHU) to pediatric patients with sickle cell disease. Procedure/methods: A retrospective cohort study was conducted using electronic health records and pharmacy databases. Pediatric patients younger than 21 years of age at the time of hydroxyurea initiation from March 2016 to July 2020 who received compounded LHU from Boston Medical Center Pharmacy were included. The primary outcomes of the study were drug adherence (assessed by evaluating the proportion of days covered [PDC]), rates of acute care utilization before and after enrolling in the LHU delivery program. Results: The final cohort included 41 patients, showing a significant decrease in hospitalizations ( p = .01) and acute chest syndrome episodes ( p = .03) after the initiation of the LHU delivery program. In comparing hydroxyurea‐naïve patients with those previously exposed to hydroxyurea, the latter group had lower hospitalization rates ( p = .01), fewer vaso‐occlusive event (VOE) episodes ( p = .02), and fewer emergency department (ED) visits ( p = .01). The median PDC value 1 year post initiation of LHU was 95. Conclusions: Home delivery of compounded LHU from the pharmacy to pediatric sickle cell disease patients improved access to hydroxyurea, and was linked to reduced hospitalizations and acute chest syndrome episodes. This advancement in cost savings and improved patient outcomes is a significant step forward in pediatric hematology. By overcoming access barriers, home delivery programs can greatly enhance outcomes among pediatric patients with sickle cell disease.
- 25 September 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (12) , e31348
Adherence outcomes of a liquid hydroxyurea delivery program in a pediatric population
Background: Hydroxyurea remains underutilized in the pediatric sickle cell population despite its well‐known efficacy in decreasing sickle cell complications and hospitalizations. Access to refills and liquid formulation remains a critical barrier to adherence to hydroxyurea regimens. This study was undertaken to determine the clinical impact of home‐delivering compounded liquid hydroxyurea (LHU) to pediatric patients with sickle cell disease. Procedure/methods: A retrospective cohort study was conducted using electronic health records and pharmacy databases. Pediatric patients younger than 21 years of age at the time of hydroxyurea initiation from March 2016 to July 2020 who received compounded LHU from Boston Medical Center Pharmacy were included. The primary outcomes of the study were drug adherence (assessed by evaluating the proportion of days covered [PDC]), rates of acute care utilization before and after enrolling in the LHU delivery program. Results: The final cohort included 41 patients, showing a significant decrease in hospitalizations ( p = .01) and acute chest syndrome episodes ( p = .03) after the initiation of the LHU delivery program. In comparing hydroxyurea‐naïve patients with those previously exposed to hydroxyurea, the latter group had lower hospitalization rates ( p = .01), fewer vaso‐occlusive event (VOE) episodes ( p = .02), and fewer emergency department (ED) visits ( p = .01). The median PDC value 1 year post initiation of LHU was 95. Conclusions: Home delivery of compounded LHU from the pharmacy to pediatric sickle cell disease patients improved access to hydroxyurea, and was linked to reduced hospitalizations and acute chest syndrome episodes. This advancement in cost savings and improved patient outcomes is a significant step forward in pediatric hematology. By overcoming access barriers, home delivery programs can greatly enhance outcomes among pediatric patients with sickle cell disease.
- Open Access
- 26 April 2024
- Published by Wiley
Adherence Outcomes of a Liquid Hydroxyurea Delivery Program in a Pediatric Population
Background: Hydroxyurea remains underutilized in the pediatric sickle cell population despite its well-known efficacy in decreasing sickle cell complications and hospitalizations. Access to refills and liquid formulation remains a critical barrier to adherence to hydroxyurea regimens. This study was undertaken to determine the clinical impact of home-delivering compounded liquid hydroxyurea (LHU) to pediatric patients with sickle cell disease. Procedure/Methods: A retrospective cohort study was conducted using electronic health records and pharmacy databases. Pediatric patients younger than 21 years of hydroxyurea initiation from March 2016 to July 2020 who received compounded LHU from Boston Medical Center Pharmacy were included. The primary outcomes of the study were drug adherence (assessed by evaluating the proportion of days covered), rates of acute care utilization, laboratory values, and growth metrics before and after enrolling in the LHU delivery program. Results: The final cohort included 41 patients. Significant increases in hemoglobin 0.34 g/dl (95% CI: 0.04-0.63, p=0.02) and mean corpuscular volume 3.2 FI (95% CI: 0.92-5.4, p=0.007) occurred. Hospitalizations decreased by 51.3% (p=0.01), and acute chest syndrome episodes decreased by 86.4% (p=0.02) post-initiation of the LHU delivery program. Drug adherence had a median value of 0.95 one-year post-initiation of LHU. Conclusions: Home delivery of compounded LHU improved drug adherence, decreased hospitalizations, and improved laboratory outcomes in pediatric patients with sickle cell disease by overcoming barriers to access. Nationwide implementation of similar home delivery programs can significantly improve outcomes among pediatric patients with sickle cell disease.
- 26 April 2024
- Published by Wiley
Open AccessAdherence Outcomes of a Liquid Hydroxyurea Delivery Program in a Pediatric Population
Background: Hydroxyurea remains underutilized in the pediatric sickle cell population despite its well-known efficacy in decreasing sickle cell complications and hospitalizations. Access to refills and liquid formulation remains a critical barrier to adherence to hydroxyurea regimens. This study was undertaken to determine the clinical impact of home-delivering compounded liquid hydroxyurea (LHU) to pediatric patients with sickle cell disease. Procedure/Methods: A retrospective cohort study was conducted using electronic health records and pharmacy databases. Pediatric patients younger than 21 years of hydroxyurea initiation from March 2016 to July 2020 who received compounded LHU from Boston Medical Center Pharmacy were included. The primary outcomes of the study were drug adherence (assessed by evaluating the proportion of days covered), rates of acute care utilization, laboratory values, and growth metrics before and after enrolling in the LHU delivery program. Results: The final cohort included 41 patients. Significant increases in hemoglobin 0.34 g/dl (95% CI: 0.04-0.63, p=0.02) and mean corpuscular volume 3.2 FI (95% CI: 0.92-5.4, p=0.007) occurred. Hospitalizations decreased by 51.3% (p=0.01), and acute chest syndrome episodes decreased by 86.4% (p=0.02) post-initiation of the LHU delivery program. Drug adherence had a median value of 0.95 one-year post-initiation of LHU. Conclusions: Home delivery of compounded LHU improved drug adherence, decreased hospitalizations, and improved laboratory outcomes in pediatric patients with sickle cell disease by overcoming barriers to access. Nationwide implementation of similar home delivery programs can significantly improve outcomes among pediatric patients with sickle cell disease.
- Open Access
- 15 March 2024
- Published by Elsevier in Health Care Transitions
- Vol. 2, 100056
Initial outcomes in a sickle cell disease transition clinic
- 15 March 2024
- Published by Elsevier in Health Care Transitions
- Vol. 2, 100056
Open AccessInitial outcomes in a sickle cell disease transition clinic
- 13 November 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (2) , e29417
Measuring transition readiness in adolescents and young adults with sickle cell disease using the transition readiness assessment questionnaire
Background/objectives: Adolescents and young adults (AYA) with sickle cell disease (SCD) face challenges related to the disease and its treatment. The Transition Readiness Assessment Questionnaire (TRAQ) is a self‐report tool for assessing transition readiness for youth with special health care needs (YSHCN), including SCD. This study uses the TRAQ to understand transition readiness in patients with SCD treated at the Boston Medical Center and evaluates associations between TRAQ scores and transition outcomes (e.g., emergency department reliance [EDr] and emergency department utilization [EDu]).Methods: We reviewed electronic medical records of AYA with SCD who completed the TRAQ in the pediatric hematology clinic between January 1, 2019, and March 1, 2020, and categorized healthcare encounters to calculate EDu and EDr. We used t tests and ANOVA models to analyze mean TRAQ scores, sex, age, genotype, EDu, and EDr.Results: The sample was 45 AYA patients with SCD between 13 and 22 years old. The mean TRAQ score for the overall patient sample was 3.67. Mean TRAQ scores did not significantly vary by sex or genotype but did significantly increase with age. TRAQ scores did not correlate to EDu or EDr.Conclusions: AYA patients with SCD have low transition readiness. The age of 18 may not be the most reliable attribute of readiness, though older patients do have higher readiness. The relationship between TRAQ scores, EDr, and EDu is not clear and requires further evaluation.
- 13 November 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (2) , e29417
Measuring transition readiness in adolescents and young adults with sickle cell disease using the transition readiness assessment questionnaire
Background/objectives: Adolescents and young adults (AYA) with sickle cell disease (SCD) face challenges related to the disease and its treatment. The Transition Readiness Assessment Questionnaire (TRAQ) is a self‐report tool for assessing transition readiness for youth with special health care needs (YSHCN), including SCD. This study uses the TRAQ to understand transition readiness in patients with SCD treated at the Boston Medical Center and evaluates associations between TRAQ scores and transition outcomes (e.g., emergency department reliance [EDr] and emergency department utilization [EDu]).Methods: We reviewed electronic medical records of AYA with SCD who completed the TRAQ in the pediatric hematology clinic between January 1, 2019, and March 1, 2020, and categorized healthcare encounters to calculate EDu and EDr. We used t tests and ANOVA models to analyze mean TRAQ scores, sex, age, genotype, EDu, and EDr.Results: The sample was 45 AYA patients with SCD between 13 and 22 years old. The mean TRAQ score for the overall patient sample was 3.67. Mean TRAQ scores did not significantly vary by sex or genotype but did significantly increase with age. TRAQ scores did not correlate to EDu or EDr.Conclusions: AYA patients with SCD have low transition readiness. The age of 18 may not be the most reliable attribute of readiness, though older patients do have higher readiness. The relationship between TRAQ scores, EDr, and EDu is not clear and requires further evaluation.
- Open Access
- 21 May 2021
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 10 (5) , e27650
Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial
Background: Sickle cell anemia (SCA) is a genetic blood disorder that puts children at a risk of serious medical complications, early morbidity and mortality, and high health care utilization. Until recently, hydroxyurea was the only disease-modifying treatment for this life-threatening disease and has remained the only option for children younger than 5 years. Evidence-based guidelines recommend using a shared decision-making (SDM) approach for offering hydroxyurea to children with SCA (HbSS or HbS/β0 thalassemia) aged as early as 9 months. However, the uptake remains suboptimal, likely because caregivers lack information about hydroxyurea and have concerns about its safety and potential long-term side effects. Moreover, clinicians do not routinely receive training or tools, especially those that provide medical evidence and consider caregivers’ preferences and values, to facilitate a shared discussion with caregivers. Objective: The aim of this study is to understand how best to help parents of young children with sickle cell disease and their clinicians have a shared discussion about hydroxyurea (one that considers medical evidence and parent values and preferences). Methods: We designed our study to compare the effectiveness of two methods for disseminating hydroxyurea guidelines to facilitate SDM: a clinician pocket guide (ie, usual care) and a clinician hydroxyurea SDM toolkit (H-SDM toolkit). Our primary outcomes are caregiver reports of decisional uncertainty and knowledge of hydroxyurea. The study also assesses the number of children (aged 0-5 years) who were offered and prescribed hydroxyurea and the resultant health outcomes. Results: The Ethics Committee of the Cincinnati Children’s Hospital Medical Center approved this study in November 2017. As of February 2021, we have enrolled 120 caregiver participants. Conclusions: The long-term objective of this study is to improve the quality of care for children with SCA. Using multicomponent dissemination methods developed in partnership with key stakeholders and designed to address barriers to high-quality care, caregivers of patients with SCA can make informed and shared decisions about their health. Trial Registration: ClinicalTrials.gov NCT03442114; https://clinicaltrials.gov/ct2/show/NCT03442114 International Registered Report Identifier (IRRID): DERR1-10.2196/27650
- 21 May 2021
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 10 (5) , e27650
Open AccessEngaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial
Background: Sickle cell anemia (SCA) is a genetic blood disorder that puts children at a risk of serious medical complications, early morbidity and mortality, and high health care utilization. Until recently, hydroxyurea was the only disease-modifying treatment for this life-threatening disease and has remained the only option for children younger than 5 years. Evidence-based guidelines recommend using a shared decision-making (SDM) approach for offering hydroxyurea to children with SCA (HbSS or HbS/β0 thalassemia) aged as early as 9 months. However, the uptake remains suboptimal, likely because caregivers lack information about hydroxyurea and have concerns about its safety and potential long-term side effects. Moreover, clinicians do not routinely receive training or tools, especially those that provide medical evidence and consider caregivers’ preferences and values, to facilitate a shared discussion with caregivers. Objective: The aim of this study is to understand how best to help parents of young children with sickle cell disease and their clinicians have a shared discussion about hydroxyurea (one that considers medical evidence and parent values and preferences). Methods: We designed our study to compare the effectiveness of two methods for disseminating hydroxyurea guidelines to facilitate SDM: a clinician pocket guide (ie, usual care) and a clinician hydroxyurea SDM toolkit (H-SDM toolkit). Our primary outcomes are caregiver reports of decisional uncertainty and knowledge of hydroxyurea. The study also assesses the number of children (aged 0-5 years) who were offered and prescribed hydroxyurea and the resultant health outcomes. Results: The Ethics Committee of the Cincinnati Children’s Hospital Medical Center approved this study in November 2017. As of February 2021, we have enrolled 120 caregiver participants. Conclusions: The long-term objective of this study is to improve the quality of care for children with SCA. Using multicomponent dissemination methods developed in partnership with key stakeholders and designed to address barriers to high-quality care, caregivers of patients with SCA can make informed and shared decisions about their health. Trial Registration: ClinicalTrials.gov NCT03442114; https://clinicaltrials.gov/ct2/show/NCT03442114 International Registered Report Identifier (IRRID): DERR1-10.2196/27650
- Open Access
- 19 May 2021
- Published by Wiley
Measuring Transition Readiness in Adolescents and Young Adults with Sickle Cell Disease Using the Transition Readiness Assessment Questionnaire
Background/Objectives: Adolescents and young adults (AYA) with sickle cell disease (SCD) face challenges related to the disease and its treatment. The Transition Readiness Assessment Questionnaire (TRAQ) is a self-report tool for assessing transition readiness for youth with special health care needs (YSHCN), including SCD. This study uses the TRAQ to understand transition readiness in patients with SCD treated at the Boston Medical Center, evaluates associations between TRAQ scores and transition outcomes (e.g., EDr, EDu), and compares TRAQ scores in this population with other YSHCN. Methods: We reviewed electronic medical records of AYA with SCD who completed the TRAQ in the pediatric hematology clinic between January 1, 2019, and March 1, 2020, and categorized healthcare encounters to calculate EDu and EDr. We used t-tests and ANOVA models to analyze mean TRAQ scores, sex, age, genotype, EDu, and EDr. Results: The sample was 45 AYA patients with SCD between 13 and 22 years old. The mean TRAQ score for the overall patient sample was 3.67. Mean TRAQ scores did not significantly vary by sex or genotype but did significantly increase with age. TRAQ scores were lower in the SCD population than in other YSHCN. TRAQ scores did not correlate to EDu or EDr. Conclusions: AYA patients with SCD have lower transition readiness than other populations of YSHCN. The age of 18 may not be the most reliable attribute of readiness, though older patients do have higher readiness. The relationship between TRAQ scores, EDr, and EDu is not clear and requires further evaluation.
- 19 May 2021
- Published by Wiley
Open AccessMeasuring Transition Readiness in Adolescents and Young Adults with Sickle Cell Disease Using the Transition Readiness Assessment Questionnaire
Background/Objectives: Adolescents and young adults (AYA) with sickle cell disease (SCD) face challenges related to the disease and its treatment. The Transition Readiness Assessment Questionnaire (TRAQ) is a self-report tool for assessing transition readiness for youth with special health care needs (YSHCN), including SCD. This study uses the TRAQ to understand transition readiness in patients with SCD treated at the Boston Medical Center, evaluates associations between TRAQ scores and transition outcomes (e.g., EDr, EDu), and compares TRAQ scores in this population with other YSHCN. Methods: We reviewed electronic medical records of AYA with SCD who completed the TRAQ in the pediatric hematology clinic between January 1, 2019, and March 1, 2020, and categorized healthcare encounters to calculate EDu and EDr. We used t-tests and ANOVA models to analyze mean TRAQ scores, sex, age, genotype, EDu, and EDr. Results: The sample was 45 AYA patients with SCD between 13 and 22 years old. The mean TRAQ score for the overall patient sample was 3.67. Mean TRAQ scores did not significantly vary by sex or genotype but did significantly increase with age. TRAQ scores were lower in the SCD population than in other YSHCN. TRAQ scores did not correlate to EDu or EDr. Conclusions: AYA patients with SCD have lower transition readiness than other populations of YSHCN. The age of 18 may not be the most reliable attribute of readiness, though older patients do have higher readiness. The relationship between TRAQ scores, EDr, and EDu is not clear and requires further evaluation.
- 27 July 2020
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (10) , e28587
Household material hardships impact emergency department reliance in pediatric patients with sickle cell disease
Background: In sickle cell disease (SCD), high emergency department (ED) utilization is associated with worse outcomes and increased costs. A metric called ED reliance (EDr), the percentage of healthcare visits that occur in the ED, attempts to identify ED overutilization. It is unknown if household material hardships (HMH)—housing, utility, or food insecurity—impact reliance on the ED. As these may represent modifiable risk factors for high ED utilization, we aimed to estimate the association between HMH and EDr in pediatric patients with SCD.Methods: We reviewed the electronic medical records of pediatric patients with SCD who received care in the Boston Medical Center network in Massachusetts, USA, to collect data on HMH and healthcare utilization. Using linear regression to control for potential confounders, we modeled the association between material hardships and EDr.Results: Of 101 eligible patients, 60 (59%) reported one or more HMH. The mean EDr was 12% overall, with significant differences between those with and without HMH (15.9 vs 5.9, P = 0.0001). Each additional hardship experienced was associated with an increased average EDr of 7.7 percentage points (R2 = 0.34, P < 0.0001). Housing and utility hardships were each independently associated with increased EDr.Conclusion: HMH are associated with significantly increased EDr in children with SCD, independent of transportation hardship or insurance type. Through screening for HMH, providers and health systems could identify at‐risk patients with modifiable risk factors for high EDr in order to provide them additional support.
- 27 July 2020
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (10) , e28587
Household material hardships impact emergency department reliance in pediatric patients with sickle cell disease
Background: In sickle cell disease (SCD), high emergency department (ED) utilization is associated with worse outcomes and increased costs. A metric called ED reliance (EDr), the percentage of healthcare visits that occur in the ED, attempts to identify ED overutilization. It is unknown if household material hardships (HMH)—housing, utility, or food insecurity—impact reliance on the ED. As these may represent modifiable risk factors for high ED utilization, we aimed to estimate the association between HMH and EDr in pediatric patients with SCD.Methods: We reviewed the electronic medical records of pediatric patients with SCD who received care in the Boston Medical Center network in Massachusetts, USA, to collect data on HMH and healthcare utilization. Using linear regression to control for potential confounders, we modeled the association between material hardships and EDr.Results: Of 101 eligible patients, 60 (59%) reported one or more HMH. The mean EDr was 12% overall, with significant differences between those with and without HMH (15.9 vs 5.9, P = 0.0001). Each additional hardship experienced was associated with an increased average EDr of 7.7 percentage points (R2 = 0.34, P < 0.0001). Housing and utility hardships were each independently associated with increased EDr.Conclusion: HMH are associated with significantly increased EDr in children with SCD, independent of transportation hardship or insurance type. Through screening for HMH, providers and health systems could identify at‐risk patients with modifiable risk factors for high EDr in order to provide them additional support.
- 1 October 2019
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (1) , e28006
Universal screening for social determinants of health in pediatric sickle cell disease: A quality‐improvement initiative
Background: Social determinants of health (SDoH) are socioeconomic factors that influence health outcomes. Guidelines recommend universal screening for SDoH at clinic visits; however, models that do not require additional resources are limited in subspecialty clinics. Individuals with sickle cell disease (SCD) face the burdens of chronic illness and often racial disparities, both of which may increase their vulnerability to adverse SDoH. Hematologists can impact both quality of life and clinical outcomes for their patients by implementing screening and referral programs addressing SDoH.Methods: Through prospective, quality‐improvement methods, we introduced universal screening for SDoH into our pediatric hematology clinic. The intervention was a paper screener followed by a referral to local community organizations for the specific needs endorsed. The aims of this study were to determine the feasibility of universal screening for SDoH in a busy subspeciality clinic using pre‐existing resources to identify the needs of our patients and to facilitate referrals between our patients and community organizations via this low touch intervention.Results: Between August 2017 and November 2018, 156 screens were completed. Sixty‐six percent were positive for at least one unmet social need for which 80% were referred to a relevant community organization. Forty‐five percent of patients available via follow‐up phone call reached out to the community organization.Conclusions: There is a high burden of SDoH in families of children with SCD. Universal screening at a pediatric hematology clinic with the subsequent connection of patients with SCD to community resources is feasible using existing clinic resources.
- 1 October 2019
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (1) , e28006
Universal screening for social determinants of health in pediatric sickle cell disease: A quality‐improvement initiative
Background: Social determinants of health (SDoH) are socioeconomic factors that influence health outcomes. Guidelines recommend universal screening for SDoH at clinic visits; however, models that do not require additional resources are limited in subspecialty clinics. Individuals with sickle cell disease (SCD) face the burdens of chronic illness and often racial disparities, both of which may increase their vulnerability to adverse SDoH. Hematologists can impact both quality of life and clinical outcomes for their patients by implementing screening and referral programs addressing SDoH.Methods: Through prospective, quality‐improvement methods, we introduced universal screening for SDoH into our pediatric hematology clinic. The intervention was a paper screener followed by a referral to local community organizations for the specific needs endorsed. The aims of this study were to determine the feasibility of universal screening for SDoH in a busy subspeciality clinic using pre‐existing resources to identify the needs of our patients and to facilitate referrals between our patients and community organizations via this low touch intervention.Results: Between August 2017 and November 2018, 156 screens were completed. Sixty‐six percent were positive for at least one unmet social need for which 80% were referred to a relevant community organization. Forty‐five percent of patients available via follow‐up phone call reached out to the community organization.Conclusions: There is a high burden of SDoH in families of children with SCD. Universal screening at a pediatric hematology clinic with the subsequent connection of patients with SCD to community resources is feasible using existing clinic resources.